---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-073967"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:02:25.228640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma

## Summary
- Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.
- Cash and equivalents $26.8M at June 30; after July ATM from healthcare investor, proforma ~$39M; expected to fund into 2H 2027.
- NXP900 becomes lead candidate; Phase 1a dose escalation and DDI study completed; Phase 1b program initiation imminent.
- NXP800 exploring opportunities in endometrial and prostate cancer; updates expected in coming months.
- R&D expenses $3.6M (incl. $1.8M stock-based comp); G&A $3.0M (incl. $1.8M stock-based comp) for Q2 2025.

## SEC filing metadata
- accession: 0001104659-25-073967
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/0001104659-25-073967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/tm2522415d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-073967
- JSON: https://secwatch.observer/filing/0001104659-25-073967.json
- Plain text: https://secwatch.observer/filing/0001104659-25-073967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.